Literature DB >> 9498025

Long-term follow-up of eczema patients treated with cyclosporine.

H Granlund1, P Erkko, S Reitamo.   

Abstract

Cyclosporine is efficacious in short-term treatment of various eczematous disorders. In a follow-up study we have evaluated the long-term efficacy of cyclosporine in 75 patients, who in previous studies had been treated with cyclosporine for chronic actinic dermatitis (6 patients), atopic dermatitis (42 patients) and chronic hand eczema (27 patients), 4, 2 and 1 year after the initial treatment, respectively. Three out of 6 patients with chronic actinic dermatitis showed long-term efficacy. Two years after the initial treatment with cyclosporine (5 mg/kg/day for 1-2 treatment periods of 6 weeks) for atopic dermatitis the mean disease activity was significantly lower compared to baseline (58% decrease), and compared to the time of treatment stop no significant change had occurred. Of 37 evaluable patients 35 were still in remission. One year after the initial treatment with cyclosporine (3 mg/kg/day for 6 weeks) for chronic hand eczema the mean disease activity was significantly lower than at baseline (54% decrease), and compared to the time of treatment stop no significant change had occurred. Of 27 evaluable patients 21 patients were still in remission. The study suggests that long-term remissions are possible in eczematous diseases treated with cyclosporine, even for a relatively short treatment period. It must be stressed, however, that we did not have control groups for any of the studied patient groups.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9498025     DOI: 10.1080/00015559850135814

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  9 in total

Review 1.  Atopic and non-atopic eczema.

Authors:  Sara Brown; Nick J Reynolds
Journal:  BMJ       Date:  2006-03-11

Review 2.  Current strategies in treating severe contact dermatitis in pediatric patients.

Authors:  Luz S Fonacier; Marcella R Aquino; Tania Mucci
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

3.  Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.

Authors:  Saakshi Khattri; Avner Shemer; Mariya Rozenblit; Nikhil Dhingra; Tali Czarnowicki; Robert Finney; Patricia Gilleaudeau; Mary Sullivan-Whalen; Xiuzhong Zheng; Hui Xu; Irma Cardinale; Cristina de Guzman Strong; Juana Gonzalez; Mayte Suárez-Fariñas; Jim G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2014-04-29       Impact factor: 10.793

Review 4.  Treatment of childhood eczema.

Authors:  Håkan Granlund
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Update on the management of chronic eczema: new approaches and emerging treatment options.

Authors:  Hobart W Walling; Brian L Swick
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-07-28

Review 6.  Guideline contact dermatitis: S1-Guidelines of the German Contact Allergy Group (DKG) of the German Dermatology Society (DDG), the Information Network of Dermatological Clinics (IVDK), the German Society for Allergology and Clinical Immunology (DGAKI), the Working Group for Occupational and Environmental Dermatology (ABD) of the DDG, the Medical Association of German Allergologists (AeDA), the Professional Association of German Dermatologists (BVDD) and the DDG.

Authors:  Jochen Brasch; Detlef Becker; Werner Aberer; Andreas Bircher; Birger Kränke; Kirsten Jung; Bernhard Przybilla; Tilo Biedermann; Thomas Werfel; Swen Malte John; Peter Elsner; Thomas Diepgen; Axel Trautmann; Hans F Merk; Thomas Fuchs; Axel Schnuch
Journal:  Allergo J Int       Date:  2014

7.  Alitretinoin--its use in intractable hand eczema and other potential indications.

Authors:  Bibi Petersen; Gregor B E Jemec
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

8.  Study protocol: efficacy of oral alitretinoin versus oral cyclosporine A in patients with severe recurrent vesicular hand eczema (ALICsA): a randomised prospective open-label trial with blinded outcome assessment.

Authors:  Jart Ate Franke Oosterhaven; Marie Louise Anna Schuttelaar
Journal:  BMJ Open       Date:  2018-07-11       Impact factor: 2.692

9.  2020 Korean Consensus Guidelines for Diagnosis and Treatment of Chronic Hand Eczema.

Authors:  Hee Joo Kim; Chul Hwan Bang; Hye One Kim; Dong Hoon Lee; Joo Yeon Ko; Eun Joo Park; Sang Wook Son; Young Suk Ro
Journal:  Ann Dermatol       Date:  2021-07-01       Impact factor: 1.444

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.